Inogen (INGN) Gets a Buy Rating from Needham
In a report released today, Michael Matson from Needham maintained a Buy rating on Inogen (INGN), with a price target of $191. The company’s shares opened today at $92.30, close to its 52-week low of $88.21.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.2% and a 66.8% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Inogen has an analyst consensus of Strong Buy, with a price target consensus of $183.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $287.79 and a one-year low of $88.21. Currently, Inogen has an average volume of 602.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.